STATE COLLEGE, Pa., April 14 /PRNewswire/ -- SpectruMedix LLC announces the launch of a new application package to the Reveal(TM) Genetic Analysis System; human bacterial and viral pathogen detection and identification. The Reveal(TM) HBVP System will include complete chemistry and instrumentation methodology for accurate, low cost, high throughput detection and identification of bacterial and viral pathogens.
The Reveal(TM) HBVP System will include primers, dNTPs, buffer, stabilizers all contained in a single vial; Reveal(TM) DNA Polymerase and methods for use in capillary electrophoresis instrumentation complete the application package.
The first set of assays include the following: Chlamydia trachomatis, Bordetella pertussis, Bordetella parapertussis, Staphlocococcus mecA, E. coli Shiga like toxin II, Herpes simplex virus, Cytomegalovirus (CMV), Varicella- zoster virus(VZV).
This new technology expands the functionality of the Reveal(TM) Genetic Analysis System, which is known for DNA variant discovery and identification, fragment analysis and sequencing. The HBVP System takes advantage of the ability to use intercalating dyes to detect unlabelled double-stranded DNA. The new technology will allow greater penetration into the molecular pathology and bacterial identification markets.
About SpectruMedix LLC
SpectruMedix LLC is an innovative manufacturer of high throughput capillary electrophoresis instrumentation for genetic analysis. The company's proprietary technology for on-column detection of DNA and temperature gradient capillary electrophoresis allows SpectruMedix to address an unmet need for high throughput screening for mutations present in DNA samples as well as a number of other genetic analysis applications. Systems are available in 24, 96, 192, and 384 capillary configurations.
More information on the Reveal(TM) System can be obtained from http://www.spectrumedix.com/ .
CONTACT: Kevin Gutshall, Director of Sales and Business Development ofSpectruMedix LLC, +1-814-867-8600, ext. 266